An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 17 Jun 2018 Results assessing the long-term safety and tolerability of Eltrombopag in pediatric patients with previously treated chronic immune thrombocytopenia, presented at the 23rd Congress of the European Haematology Association.
- 27 Jul 2017 Status changed from recruiting to completed.
- 13 Jun 2017 Planned End Date changed from 19 Apr 2019 to 1 Jul 2017.